Literature DB >> 31970776

Higher lymph node harvest in patients with a pathologic complete response after neoadjuvant therapy for esophageal cancer is associated with improved survival.

Waseem Lutfi1, Deirdre Martinez-Meehan1, Rajeev Dhupar1,2, Neil Christie1, Inderpal Sarkaria1, Chigozirim Ekeke1, Nicholas Baker1, James D Luketich1, Olugbenga T Okusanya1.   

Abstract

BACKGROUND AND OBJECTIVES: Lymph node harvest during esophagectomy has been associated with improved survival for esophageal cancer but the value of enhanced lymph node harvest following complete pathologic response (pCR) is debated. This study investigated if increasing lymph node harvest in esophageal cancer patients with a pCR after neoadjuvant therapy and esophagectomy is associated with improved survival.
METHODS: We queried the National Cancer Data Base for patients with esophageal cancer between 2004 and 2014 who underwent neoadjuvant chemotherapy or chemoradiation therapy followed by esophagectomy found to have pCR. Multivariable Cox modeling was utilized to evaluate the impact of increasing lymph node counts on overall survival (OS).
RESULTS: A total of 1373 patients met inclusion criteria. A National Comprehensive Cancer Network compliant lymphadenectomy of ≥15 nodes was associated with improved survival (66.7% vs 51.1%; P < .001). Cox modeling showed that the first node cutoff to demonstrate a statistically significant improvement in OS was ≥7 nodes (hazard ratio [HR], 95% confidence interval [CI]: 0.81, 0.68-0.97; 5-year OS: 54.2%) with a trend of decreasing and statistically significant HRs until ≥25 nodes (HR, 95% CI: 0.52, 0.37-0.72; 5-year OS: 68.4%).
CONCLUSIONS: High negative node counts after neoadjuvant therapy and esophagectomy are associated with improved survival in patients with pCR.
© 2020 Wiley Periodicals, Inc.

Entities:  

Keywords:  complete pathologic response; esophageal cancer; esophagectomy; lymph node harvest; neoadjuvant therapy

Year:  2020        PMID: 31970776     DOI: 10.1002/jso.25846

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  2 in total

Review 1.  Recent advances in multidisciplinary therapy for adenocarcinoma of the esophagus and esophagogastric junction.

Authors:  Yi-Han Zheng; En-Hao Zhao
Journal:  World J Gastroenterol       Date:  2022-08-21       Impact factor: 5.374

2.  Residual lymph node disease and mortality following neoadjuvant chemoradiation and curative esophagectomy for distal esophageal adenocarcinoma.

Authors:  Apostolos Kandilis; Carlos Bravo Iniguez; Hassan Khalil; Emanuele Mazzola; Michael T Jaklitsch; Scott J Swanson; Raphael Bueno; Jon O Wee
Journal:  JTCVS Open       Date:  2020-12-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.